These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

432 related items for PubMed ID: 9133750

  • 1. Factors that influence the outcome of placebo-controlled antidepressant clinical trials.
    Niklson IA, Reimitz PE, Sennef C.
    Psychopharmacol Bull; 1997; 33(1):41-51. PubMed ID: 9133750
    [Abstract] [Full Text] [Related]

  • 2. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA, Chen YF, Yang Y, Yang P, Laughren TP.
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [Abstract] [Full Text] [Related]

  • 3. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
    Alpert JE, Franznick DA, Hollander SB, Fava M.
    J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
    [Abstract] [Full Text] [Related]

  • 4. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients.
    Schweizer E, Feighner J, Mandos LA, Rickels K.
    J Clin Psychiatry; 1994 Mar; 55(3):104-8. PubMed ID: 8071246
    [Abstract] [Full Text] [Related]

  • 5. A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression.
    Feiger AD.
    Psychopharmacol Bull; 1996 Mar; 32(4):659-65. PubMed ID: 8993088
    [Abstract] [Full Text] [Related]

  • 6. Response of anxiety and agitation symptoms during nefazodone treatment of major depression.
    Fawcett J, Marcus RN, Anton SF, O'Brien K, Schwiderski U.
    J Clin Psychiatry; 1995 Mar; 56 Suppl 6():37-42. PubMed ID: 7649972
    [Abstract] [Full Text] [Related]

  • 7. Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials.
    Khan A, Brodhead AE, Kolts RL, Brown WA.
    J Psychiatr Res; 2005 Mar; 39(2):145-50. PubMed ID: 15589562
    [Abstract] [Full Text] [Related]

  • 8. Placebo response and antidepressant clinical trial outcome.
    Khan A, Detke M, Khan SR, Mallinckrodt C.
    J Nerv Ment Dis; 2003 Apr; 191(4):211-8. PubMed ID: 12695731
    [Abstract] [Full Text] [Related]

  • 9. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
    Jahn H, Schick M, Kiefer F, Kellner M, Yassouridis A, Wiedemann K.
    Arch Gen Psychiatry; 2004 Dec; 61(12):1235-44. PubMed ID: 15583115
    [Abstract] [Full Text] [Related]

  • 10. Relationship between depression severity entry criteria and antidepressant clinical trial outcomes.
    Khan A, Schwartz K, Kolts RL, Ridgway D, Lineberry C.
    Biol Psychiatry; 2007 Jul 01; 62(1):65-71. PubMed ID: 17141744
    [Abstract] [Full Text] [Related]

  • 11. Nefazodone: aspects of efficacy.
    Rickels K, Robinson DS, Schweizer E, Marcus RN, Roberts DL.
    J Clin Psychiatry; 1995 Jul 01; 56 Suppl 6():43-6. PubMed ID: 7649973
    [Abstract] [Full Text] [Related]

  • 12. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
    Patkar AA, Masand PS, Pae CU, Peindl K, Hooper-Wood C, Mannelli P, Ciccone P.
    J Clin Psychopharmacol; 2006 Dec 01; 26(6):653-6. PubMed ID: 17110825
    [Abstract] [Full Text] [Related]

  • 13. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.
    Eur Neuropsychopharmacol; 2004 Dec 01; 14(6):457-70. PubMed ID: 15589385
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV.
    Clin Ther; 2007 Nov 01; 29(11):2319-32. PubMed ID: 18158074
    [Abstract] [Full Text] [Related]

  • 15. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K, Chrzanowski W, Schmitz M, Savela A, Milanova V, Gee M, Krishen A, Millen L, Leary MO, Modell J.
    J Psychopharmacol; 2009 Jul 01; 23(5):531-8. PubMed ID: 18635695
    [Abstract] [Full Text] [Related]

  • 16. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine.
    Honig A, Kuyper AM, Schene AH, van Melle JP, de Jonge P, Tulner DM, Schins A, Crijns HJ, Kuijpers PM, Vossen H, Lousberg R, Ormel J, MIND-IT investigators.
    Psychosom Med; 2007 Jul 01; 69(7):606-13. PubMed ID: 17846258
    [Abstract] [Full Text] [Related]

  • 17. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM.
    Curr Med Res Opin; 2007 Jun 01; 23(6):1303-18. PubMed ID: 17559729
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb 01; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 19. Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies.
    Chouinard G, Saxena BM, Nair NP, Kutcher SP, Bakish D, Bradwejn J, Kennedy SH, Sharma V, Remick RA, Kukha-Mohamad SA.
    Clin Neuropharmacol; 1993 Feb 01; 16 Suppl 2():S51-4. PubMed ID: 8313397
    [Abstract] [Full Text] [Related]

  • 20. A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety.
    Fawcett J, Barkin RL.
    J Clin Psychiatry; 1998 Mar 01; 59(3):123-7. PubMed ID: 9541155
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.